SI1082302T1 - A vla-4 inhibitor: omepupa-v - Google Patents
A vla-4 inhibitor: omepupa-vInfo
- Publication number
- SI1082302T1 SI1082302T1 SI9930526T SI9930526T SI1082302T1 SI 1082302 T1 SI1082302 T1 SI 1082302T1 SI 9930526 T SI9930526 T SI 9930526T SI 9930526 T SI9930526 T SI 9930526T SI 1082302 T1 SI1082302 T1 SI 1082302T1
- Authority
- SI
- Slovenia
- Prior art keywords
- omepupa
- inhibitor
- vla
- cell
- methylphenylamino
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000021164 cell adhesion Effects 0.000 abstract 2
- -1 2-methylphenylamino Chemical group 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 229940000635 beta-alanine Drugs 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8706498P | 1998-05-28 | 1998-05-28 | |
| PCT/US1999/011924 WO1999061421A1 (en) | 1998-05-28 | 1999-05-28 | A NOVEL VLA-4 INHIBITOR: oMePUPA-V |
| EP99926019A EP1082302B1 (en) | 1998-05-28 | 1999-05-28 | A vla-4 inhibitor: omepupa-v |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1082302T1 true SI1082302T1 (en) | 2004-06-30 |
Family
ID=22202907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9930526T SI1082302T1 (en) | 1998-05-28 | 1999-05-28 | A vla-4 inhibitor: omepupa-v |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6495525B1 (xx) |
| EP (1) | EP1082302B1 (xx) |
| JP (1) | JP2002516309A (xx) |
| KR (1) | KR100636713B1 (xx) |
| CN (1) | CN1148350C (xx) |
| AT (1) | ATE256659T1 (xx) |
| AU (1) | AU764108B2 (xx) |
| BG (1) | BG65021B1 (xx) |
| CA (1) | CA2333656C (xx) |
| CZ (1) | CZ298413B6 (xx) |
| DE (1) | DE69913687T2 (xx) |
| DK (1) | DK1082302T3 (xx) |
| EA (1) | EA002988B1 (xx) |
| EE (1) | EE04639B1 (xx) |
| ES (1) | ES2211096T3 (xx) |
| HK (1) | HK1035726A1 (xx) |
| HU (1) | HUP0102255A3 (xx) |
| IL (1) | IL139967A (xx) |
| IS (1) | IS5737A (xx) |
| MX (1) | MXPA00011774A (xx) |
| NO (1) | NO317990B1 (xx) |
| NZ (1) | NZ509199A (xx) |
| PL (1) | PL198189B1 (xx) |
| PT (1) | PT1082302E (xx) |
| SI (1) | SI1082302T1 (xx) |
| SK (1) | SK285280B6 (xx) |
| TR (1) | TR200100190T2 (xx) |
| UA (1) | UA65623C2 (xx) |
| WO (1) | WO1999061421A1 (xx) |
| YU (1) | YU75500A (xx) |
| ZA (1) | ZA200007300B (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| AU751950B2 (en) * | 1997-11-24 | 2002-09-05 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| PL203114B1 (pl) * | 1998-09-14 | 2009-08-31 | Regents Board Of | Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1 |
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| US6525069B1 (en) | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1741428A3 (en) | 1999-08-13 | 2007-05-09 | Biogen Idec MA, Inc. | Cell adhesion inhibitors |
| SK8692002A3 (en) | 1999-12-28 | 2003-06-03 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| CA2430978C (en) | 2000-12-28 | 2012-05-15 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
| TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| US7685367B2 (en) * | 2006-03-08 | 2010-03-23 | Microsoft Corporation | Multi-cache cooperation for response output caching |
| RU2009107030A (ru) * | 2006-08-02 | 2010-09-10 | Джензим Корпорейшн (Us) | Комбинированная терапия |
| WO2008103378A2 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| CN102057054B (zh) | 2008-04-11 | 2015-06-10 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1149971B (it) | 1979-06-11 | 1986-12-10 | Syntex Inc | Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante |
| US4725583A (en) | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
| US4826815A (en) | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
| GB2218102B (en) | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
| ATE131471T1 (de) | 1989-12-22 | 1995-12-15 | Commw Scient Ind Res Org | An fette gebundene aminosäuren, peptide oder deren derivate |
| CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5260277A (en) * | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
| EP0519748B1 (en) | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| JPH07503944A (ja) | 1991-11-22 | 1995-04-27 | イエダ リサーチ アンド デベロツプメント カンパニー リミテツド | Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物 |
| AU3420693A (en) | 1991-12-24 | 1993-07-28 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
| DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
| IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
| WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
| US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| AU698990B2 (en) | 1993-04-09 | 1998-11-19 | Toyama Chemical Co. Ltd. | Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
| US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| ES2271971T3 (es) * | 1996-07-25 | 2007-04-16 | Biogen Idec Ma Inc. | Inhibidores de la adhesion celular. |
-
1999
- 1999-05-28 CZ CZ20004425A patent/CZ298413B6/cs not_active IP Right Cessation
- 1999-05-28 PL PL344440A patent/PL198189B1/pl not_active IP Right Cessation
- 1999-05-28 YU YU75500A patent/YU75500A/sh unknown
- 1999-05-28 DE DE69913687T patent/DE69913687T2/de not_active Expired - Fee Related
- 1999-05-28 SK SK1810-2000A patent/SK285280B6/sk not_active IP Right Cessation
- 1999-05-28 NZ NZ509199A patent/NZ509199A/en unknown
- 1999-05-28 TR TR2001/00190T patent/TR200100190T2/xx unknown
- 1999-05-28 AT AT99926019T patent/ATE256659T1/de not_active IP Right Cessation
- 1999-05-28 EE EEP200000698A patent/EE04639B1/xx not_active IP Right Cessation
- 1999-05-28 MX MXPA00011774A patent/MXPA00011774A/es not_active IP Right Cessation
- 1999-05-28 CN CNB998080020A patent/CN1148350C/zh not_active Expired - Fee Related
- 1999-05-28 WO PCT/US1999/011924 patent/WO1999061421A1/en active IP Right Grant
- 1999-05-28 HU HU0102255A patent/HUP0102255A3/hu unknown
- 1999-05-28 EA EA200001236A patent/EA002988B1/ru not_active IP Right Cessation
- 1999-05-28 JP JP2000550827A patent/JP2002516309A/ja active Pending
- 1999-05-28 CA CA002333656A patent/CA2333656C/en not_active Expired - Fee Related
- 1999-05-28 IL IL13996799A patent/IL139967A/xx not_active IP Right Cessation
- 1999-05-28 ES ES99926019T patent/ES2211096T3/es not_active Expired - Lifetime
- 1999-05-28 UA UA2000127603A patent/UA65623C2/uk unknown
- 1999-05-28 SI SI9930526T patent/SI1082302T1/xx unknown
- 1999-05-28 EP EP99926019A patent/EP1082302B1/en not_active Expired - Lifetime
- 1999-05-28 DK DK99926019T patent/DK1082302T3/da active
- 1999-05-28 AU AU42192/99A patent/AU764108B2/en not_active Ceased
- 1999-05-28 PT PT99926019T patent/PT1082302E/pt unknown
- 1999-05-28 KR KR1020007013421A patent/KR100636713B1/ko not_active IP Right Cessation
-
2000
- 2000-11-28 IS IS5737A patent/IS5737A/is unknown
- 2000-11-28 US US09/724,107 patent/US6495525B1/en not_active Expired - Fee Related
- 2000-11-28 NO NO20006023A patent/NO317990B1/no unknown
- 2000-12-08 ZA ZA200007300A patent/ZA200007300B/en unknown
- 2000-12-18 BG BG105060A patent/BG65021B1/bg unknown
-
2001
- 2001-09-11 HK HK01106420A patent/HK1035726A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1035726A1 (en) | A vla-4 inhibitor: omepupa-v | |
| HUP9802315A3 (en) | Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions | |
| ZA200108082B (en) | Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth. | |
| HUP0001285A3 (en) | Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them | |
| HUP0300148A3 (en) | Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| BR9908280A (pt) | Inibidores de enzimas de fosfolipase | |
| AU6523396A (en) | Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors | |
| HUP9900728A2 (hu) | Thrombin inhibitorhatású peptidszármazékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények | |
| AP1787A (en) | Novel perindopril salt and pharmaceutical compositions containing same. | |
| GR3036305T3 (en) | Chiral methyl phenyl oxazolidinones | |
| MY125428A (en) | ?-carboline drug products | |
| WO2001090138A3 (en) | SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES | |
| IL124883A0 (en) | Amidino protease inhibitors and pharmaceutical compositions containing the same | |
| DE69033970D1 (de) | Huperzin a analoge verbindungen | |
| BR9912010A (pt) | Polimorfo de um produto farmacêutico | |
| AU6611696A (en) | N-(4-substituted-benzyl)-2-aminolactam derivatives | |
| HUP0101899A3 (en) | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use | |
| TR199700764T1 (xx) | Karbinolleri ay�rmaya mahsus i�lem. | |
| MX9603606A (es) | N-metil-n-[(1s)-1-fenil-2-((3s)-3-hidroxipirrolidin-1-il) etil]-2,2-difenil-acetamida. | |
| HUP0202729A2 (hu) | Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények | |
| AU2003271811A1 (en) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same | |
| AU8847098A (en) | Pharmaceutical compositions comprising cefuroxime axetil | |
| AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| EP0974353A3 (en) | The use of homocysteine derivatives for the preparation of medicaments inhibiting bacterial adhesiveness | |
| WO2000063350A3 (en) | Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis |